These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12444359)

  • 1. Benefit-cost analysis of addiction treatment in Arkansas: specialty and standard residential programs for pregnant and parenting women.
    French MT; McCollister KE; Cacciola J; Durell J; Stephens RL
    Subst Abus; 2002 Mar; 23(1):31-51. PubMed ID: 12444359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit-cost analysis of residential and outpatient addiction treatment in the State of Washington.
    French MT; Salomé HJ; Krupski A; McKay JR; Donovan DM; McLellan AT; Durell J
    Eval Rev; 2000 Dec; 24(6):609-34. PubMed ID: 11151519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic benefits of substance abuse treatment: findings from Cuyahoga County, Ohio.
    Koenig L; Siegel JM; Harwood H; Gilani J; Chen YJ; Leahy P; Stephens R
    J Subst Abuse Treat; 2005; 28 Suppl 1():S41-50. PubMed ID: 15797638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs of crime and the benefits of substance abuse treatment for pregnant women.
    Daley M; Argeriou M; McCarty D; Callahan JJ; Shepard DS; Williams CN
    J Subst Abuse Treat; 2000 Dec; 19(4):445-58. PubMed ID: 11166509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of substance abuse treatment modality on birth weight and health care expenditures.
    Daley M; Argeriou M; McCarty D; Callahan JJ; Shepard DS; Williams CN
    J Psychoactive Drugs; 2001; 33(1):57-66. PubMed ID: 11333002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program.
    Roebuck MC; French MT; McLellan AT
    J Subst Abuse Treat; 2003 Jul; 25(1):51-7. PubMed ID: 14512108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS).
    Godfrey C; Stewart D; Gossop M
    Addiction; 2004 Jun; 99(6):697-707. PubMed ID: 15139868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care costs associated with posttraumatic stress disorder symptoms in women.
    Walker EA; Katon W; Russo J; Ciechanowski P; Newman E; Wagner AW
    Arch Gen Psychiatry; 2003 Apr; 60(4):369-74. PubMed ID: 12695314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early start: a cost-beneficial perinatal substance abuse program.
    Goler NC; Armstrong MA; Osejo VM; Hung YY; Haimowitz M; Caughey AB
    Obstet Gynecol; 2012 Jan; 119(1):102-10. PubMed ID: 22183217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residential treatment for eating disorders.
    Frisch MJ; Herzog DB; Franko DL
    Int J Eat Disord; 2006 Jul; 39(5):434-42. PubMed ID: 16528698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues in subject recruitment and retention with pregnant and parenting substance-abusing women.
    Howard J; Beckwith L
    NIDA Res Monogr; 1996; 166():68-86. PubMed ID: 8818166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in quality of life for pregnant women in substance user treatment: developing a quality of life index for the addictions.
    Daley M; Shepard DS; Bury-Maynard D
    Subst Use Misuse; 2005; 40(3):375-94. PubMed ID: 15776984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of day hospital and community residential chemical dependency treatment.
    Kaskutas LA; Zavala SK; Parthasarathy S; Witbrodt J
    J Ment Health Policy Econ; 2008 Mar; 11(1):27-32. PubMed ID: 18424874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of cost-benefit analysis in integration projects on drug addiction].
    Ates T; Langer B; Erbas B; Tretter F; Wehner B
    Gesundheitswesen; 2005 Feb; 67(2):159-62. PubMed ID: 15747208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unit cost of counseling and patients length of stay in a residential drug treatment setting.
    Alemi F; Haack M; Holifield L; Claudio Y; Haqqi K
    J Ment Health Policy Econ; 2002 Sep; 5(3):103-7. PubMed ID: 12728196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.